Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06057181 · ClinicalTrials.gov registry record

Helix Research Network

A clinical trial of Genetic Predisposition to Disease and Genetics Disease, sponsored by Helix.

Recruiting
Registry status
2,000,000
Enrollment target
14
Study locations

NCT06057181: Recruiting study of Genetic Predisposition to Disease and Genetics Disease, sponsored by Helix.

NCT06057181 is a study of Genetic Predisposition to Disease and Genetics Disease that is actively recruiting participants, run by Helix. The registered enrollment target is 2,000,000 participants, above the 706-participant average among 11 other Genetic Predisposition to Disease trials with a reported enrollment target (283186% higher). The trial reports 14 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT06057181, a study of Genetic Predisposition to Disease and Genetics Disease, is actively recruiting participants, sponsored by Helix.

RECRUITING
Registry status
2,000,000 participants
Enrollment target
14
Study locations

Study Summary

The Helix Research Network ("HRN") is a network of academic, public, and/or private healthcare organizations that are committed to advancing medical research and improving human health through large-scale genomics research and acceleration of the integration of genomic and other omics data into clinical care.

Primary Outcome

Establish a research network to support the advancement of biomedical research, improve human health through genomics research, and accelerate integration of genomic and other omics data into clinical care.

Interventions

  • GENETIC Exome sequencing

Study Locations (14)

North Carolina

  • Cone Health (Gene Connect) - Burlington
  • WakeMed (PreciselyYou) - Raleigh

Ohio

  • TriHealth (DNA Discovery) - Cincinnati
  • The Ohio State University (Genomic Health) - Columbus

Pennsylvania

  • St. Luke's University Health Network (DNAanswers) - Bethlehem
  • WellSpan Health (The Gene Health Project) - York

Indiana

  • Parkview Health (DNA Insights) - Fort Wayne

Minnesota

  • HealthPartners (myGenetics) - Bloomington

Nebraska

  • Nebraska Medicine - University of Nebraska Medical Center (Genetic Insights Project) - Omaha

Nevada

  • Renown Health (Healthy Nevada Project) - Reno

New York

  • Rochester Regional Health (GenoWell) - Rochester

Trial Details

FieldValue
Enrollment Target 2,000,000 participants
Start Date 2021-09-13
Est. Completion 2036-09-13
Helix

1 total trials

What NCT06057181 shows while recruiting

NCT06057181 is an observational study that tracks outcomes without assigning an intervention. Its 2,000,000 participants enrollment target places it among the larger protocols in the corpus, above the 706-participant average among 11 other Genetic Predisposition to Disease trials with a reported enrollment target (283186% higher).

The record links to 2 conditions, with Genetic Predisposition to Disease appearing as the primary indexed condition, and to 1 intervention - of which Exome sequencing is the first listed.

NCT06057181 lists 14 locations in 11 states (North Carolina, Ohio, Pennsylvania).

Frequently Asked Questions

What is clinical trial NCT06057181 about?

NCT06057181 is a clinical study titled "Helix Research Network". The Helix Research Network ("HRN") is a network of academic, public, and/or private healthcare organizations that are committed to advancing medical research and improving human health through large-scale genomics research and acceleration of the integration of genomic and other omics data into clin...

What is the current status of trial NCT06057181?

This trial is currently recruiting. The enrollment target is 2,000,000 participants. The study started on 2021-09-13. Estimated completion is 2036-09-13.

What conditions does trial NCT06057181 study?

This clinical trial studies the following conditions: Genetic Predisposition to Disease, Genetics Disease.

What interventions are being tested in trial NCT06057181?

The interventions under investigation include: Exome sequencing (GENETIC).

Who is sponsoring clinical trial NCT06057181?

This trial is sponsored by Helix, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06057181 being conducted?

This trial has 14 study locations across Indiana, Minnesota, Nebraska, Nevada, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Genetic Predisposition to Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06057181's enrollment target sits among peer trials

2,000,000 1st of 11 higher than 11 of 11 other Genetic Predisposition to Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Genetic Predisposition to Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03813862 · 2,000,000 participants

    Observational Pharmaco-Epidemiology Research & Analysis

  • NCT07022951 · 1,200,000 participants

    The Million Anesthesia Cases Study (MACS) - a Cohort Study of Preoperative Fasting and Perioperative Outcomes

  • NCT06803498 · 3,000,000 participants

    Delivery Room Intervention and Evaluation Network

  • NCT05066763 · 1,000,000 participants

    Parkinson's Foundation Surveys

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06057181, the US trial registry maintained by the National Library of Medicine. NCT06057181 (large enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.